Oncologic Drugs Advisory Committee
Committee Meeting on February 9, 2011, from 8 a.m. to 12:30 p.m.
Agenda: On February 9, 2011, the committee will discuss biologics license application (BLA) 125377, with the proposed trade name YERVOY(ipilimumab), submitted by Bristol-Myers Squibb Co. The proposed indication (use) for this product is for the treatment of advanced melanoma in patients who have received prior therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment